Hedge Fund - Sarissa Capital Management

Alex Denner Bio, Returns, AUM, Net Worth

Sarissa Capital Management was launched by Dr. Alexander John Denner in 2012 and is currently headquartered in Greenwich, Connecticut. The hedge fund invests primarily in stocks of companies operating in the health care industry. Mr. Denner gained experience as portfolio manager during his stint at Andreas Halvorsen’s Viking Global, which ended in 2006. For the next six years, Mr. Denner served as Senior Managing Director at Carl Icahn’s Icahn Capital LP, after which he decided to found his own investment firm.

At Icahn Capital, Alex Denner formed an activist strategy in healthcare and pushed for some of the fund’s best investment moves, such as positions in Genzyme, Biogen Inc (NASDAQ:BIIB), and ImClone to name a few. Alex J. Denner has also served as a director on the board of many healthcare companies, including ARIAD Pharmaceuticals Inc and Enzon Pharmaceuticals, and is currently part of the leadership teams of Biogen and The Medicines Company (NASDAQ:MDCO). Alex Denner holds an S.B. degree from the Massachusetts Institute of Technology and M.S., M.Phil and PhD degrees from Yale University.

Alex Denner's investment strategies have delivered positive returns through the years, as Sarissa Capital Management’s flagship fund gained 7.9% from May to December 2013, 9.6% in 2014 and 2.5% through February 2015. According to the fund’s plain brochure it held around $569.40 million of Advisory Client regulatory assets on a discretionary basis at the end of 2016.

Alex Denner
Fund Profile
Filing Period:
Fund Name: Sarissa Capital Management
Manager Alex Denner
Portfolio Value $1,004,526,158
Change This QTR +1.28%
Fund Holdings Sector Distribution
Filing Period:
Last update:
No. Security Ticker Shares Value Activity % Port History
1. ALKS 14,040,000 $439,452,000 +57% 43.74%
2. BIIB 643,000 $183,158,550 18.23%
3. IRWD 16,390,000 $174,389,600 17.36%
4. INVA 7,277,000 $92,636,210 +11% 9.22%
5. GILD 920,400 $70,935,228 +9% 7.06%
News, Interviews and Investor Letters